Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233467 | 1.00 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB | |
| SCHEMBL6179708 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB | |
| SCHEMBL5161578 | 0.90 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB | |
| SCHEMBL17069045 | 0.89 | SMN1; SMN2 (0.63) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB | |
| SCHEMBL4473488 | 0.89 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB | |
| SCHEMBL3591879 | 0.89 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB | |
| SCHEMBL11032344 | 0.89 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB | |
| SCHEMBL13878761 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB | |
| SCHEMBL11585903 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB | |
| SCHEMBL18374165 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1NPC1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105622717-A | Six cyclic dipeptides used for wound healing | GOOD DOCTOR PHARMACEUTICAL GROUP CO LTD | 2016-06-01 | — | — | CN | disclosed |
| EP-1513842-B1 | SUBSTITUTED HEXAHYDROPYRROLO (1,2-A)PYRAZINES, OCTAHYDROPYRIDO(1,2-A)PYRAZINES AND DECAHYDROPYRAZINO(1,2-A)AZEPINES | NOVO NORDISK AS (DK) | 2007-03-07 | — | — | EP | disclosed |
| US-7186721-B2 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | NOVO NORDISK A/S (DK) | 2007-03-06 | — | — | US | disclosed |
| US-7186721-B2 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | NOVO NORDISK A/S (DK) | 2007-03-06 | — | — | US | disclosed |
| US-7186721-B2 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | NOVO NORDISK A/S (DK) | 2007-03-06 | — | — | US | disclosed |
| US-20050267116-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | HIGH POINT PHARMACEUTICALS, LLC | 2005-12-01 | — | — | US | disclosed |
| US-6906060-B2 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | NOVO NORDISK A/S (DK) | 2005-06-14 | — | — | US | disclosed |
| EP-1513842-A1 | SUBSTITUTED HEXAHYDROPYRROLO (1,2-A)PYRAZINES, OCTAHYDROPYRIDO(1,2-A)PYRAZINES AND DECAHYDROPYRAZINO(1,2-A)AZEPINES | NOVO NORDISK A/S (DK) | 2005-03-16 | — | — | EP | disclosed |
| US-20040023946-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | VTVX HOLDINGS II LLC | 2004-02-05 | — | — | US | disclosed |
| WO-2003104235-A1 | SUBSTITUTED HEXAHYDROPYRROLO[1,2-A]PYRAZINES, OCTAHYDROPYRIDO[1,2-A]PYRAZINES AND DECAHYDROPYRAZINO[1,2-A]AZEPINES | NOVO NORDISK A/S (DK) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023946-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | HRH2, HRH4, HRH1 | SMN1; SMN2 3915/4885ALDH1A1 835/4885NPC1 3188/4885 |
| US-20050267116-A1 | Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines | HRH2, HRH4, HRH1 | SMN1; SMN2 3900/4885ALDH1A1 1228/4885NPC1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.